99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer - Top-Institutions - MDSpire

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer

  • By

  • Maurits Wondergem

  • Friso M. van der Zant

  • Remco J. J. Knol

  • Anne Marij G. Burgers

  • Siebe D. Bos

  • Igle J. de Jong

  • Jan Pruim

  • October 17, 2017

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Radiology

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Nuclear Medicine
    • Urology
    • Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Nuclear Medicine
    • Radiology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Radiology

  • #5

    University of Michigan Health System
    University of Michigan Health System

    Ann Arbor, MI

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Radiology

Original Source(s)

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer

  • by Maurits Wondergem, Friso M. van der Zant, Remco J. J. Knol, Anne Marij G. Burgers, Siebe D. Bos, Igle J. de Jong, Jan Pruim

  • October 17, 2017

Related Content

Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients

Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study

MRI as a screening tool for prostate cancer: current evidence and future challenges